EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long‐term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10‐year follow‐up study

Hong Xu, Annegret Habich, Daniel Ferreira, Londos Elisabet, Eric Westman, Maria Eriksdotter

Alzheimer's & Dementia · 2024

DOI: 10.1002/alz.14118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Hong Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockho…. Hauptthemen laut MEDLINE: Memantine, Lewy Body Disease, Cholinesterase Inhibitors, Cognitive Dysfunction. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Strategic Research Area Neuroscience-Karolinska Institutet, Center for Innovative Medicine Foundation, Center for Innovative Medicina.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION We aimed to assess the impact of cholinesterase inhibitors (ChEIs) and memantine on cognition, major adverse cardiovascular events (MACE) and mortality in dementia with Lewy bodies (DLB). METHODS A total of 1,095 incident DLB patients from the Swedish Registry on cognitive/dementia disorders were included. Using an inverse probability of treatment weighting, the effect of initiating ChEI or memantine within 90 days of DLB diagnosis and nonuse was evaluated on cognitive trajectories and risks of MACE and death. RESULTS The use of ChEIs significantly slowed cognitive decline at follow‐ups (Mini‐Mental State Examination [MMSE] ‐0.39 points/y; 95% confidence interval [CI], ‐0.96 to 0.18) compared to memantine (‐2.49 points/y; ‐4.02 to ‐0.97) and nonuse (‐2.50 points/y; ‐4.28 to ‐0.73). Treatment groups did not differ in MACE events. ChEI use was associated with lower risk of death in the first year after DLB diagnosis (adjusted hazard ratio [HR] 0.66, 95% CI 0.46, 0.94). DISCUSSION Our findings illuminate the potential benefits of ChEI treatment in DLB patients. Highlights Cholinesterase inhibitors slow cognitive decline over a 5‐year follow‐up period when compared to both memantine treatment and nonuse in patients with dementia with Lewy bodies. Cholinesterase Inhibitors reduce risk of mortality within the initial year, but this effect is not sustained after 1 year in patients with dementia with Lewy bodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MemantineLewy Body DiseaseCholinesterase InhibitorsCognitive DysfunctionCardiovascular DiseasesHumansFemaleMaleAgedFollow-Up StudiesSwedenAged, 80 and overRegistriesMental Status and Dementia Tests

Stichwörter der Autor:innen

MMSEcholinesterase inhibitorsdementia with Lewy bodiesmemantinemortality

Substanzen

MemantineCholinesterase Inhibitors

Autor:innen und Institutionen

  • Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
  • University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.
  • Facultad de Ciencias de la Salud, Universidad Fernando Pessoa Canarias, Las Palmas, España.
  • Institution of Clinical Sciences, Lund University, Malmö, Sweden.
  • Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.

Förderung

  • Strategic Research Area Neuroscience-Karolinska Institutet
  • Center for Innovative Medicine Foundation
  • Center for Innovative Medicina
  • regional agreement on medical training and clinical research of Stockholm Region
  • Swedish Brain Foundation
  • Swedish Alzheimer Foundation
  • Swedish Dementia Foundation
  • Gamla Tjänarinnor Foundation

Zitieren

APA

Xu, H., Habich, A., Ferreira, D., Elisabet, L., Westman, E., & Eriksdotter, M. (2024). Long‐term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10‐year follow‐up study. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14118

Vancouver

Xu H, Habich A, Ferreira D, Elisabet L, Westman E, Eriksdotter M. Long‐term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10‐year follow‐up study. Alzheimer's & Dementia. 2024. doi:10.1002/alz.14118

BibTeX
@article{Xu2024,
  author = {Xu, Hong and Habich, Annegret and Ferreira, Daniel and Elisabet, Londos and Westman, Eric and Eriksdotter, Maria},
  title = {Long‐term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10‐year follow‐up study},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  doi = {10.1002/alz.14118}
}
Kostenlos starten →